Hina Shah1,2, Yating Wang3, Su-Chun Cheng3, Lauren Gunasti4,5, Yu-Hui Chen3, Ana Lako6,7, Jeffrey Guenette1,2, Scott Rodig8, Vickie Y Jo8, Ravindra Uppaluri5,9, Robert Haddad5, Jonathan D Schoenfeld4,5, Heather A Jacene1,2. 1. Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts. 3. Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts. 5. Head and Neck Cancer Treatment Center, Dana-Farber Cancer Institute, Boston, Massachusetts. 6. Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 7. Bristol Myers Squibb. 8. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 9. Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
IMPORTANCE: Neoadjuvant immunotherapy is a novel approach with the potential to improve outcomes for patients with oral cavity squamous cell cancer (OCSCC). Adverse events of varying severity are reported with immunotherapy, and a biomarker to predict response would be clinically useful to avoid toxic effects in those unlikely to benefit. OBJECTIVE: To correlate changes on fluoro-[18F]-deoxy-2-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scans with primary tumor pathologic response and immunologic biomarkers in patients with OCSCC receiving neoadjuvant immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of serial FDG-PET/CT scans obtained prospectively as part of a phase 2 open-label randomized clinical trial investigating neoadjuvant immunotherapy in patients with untreated OCSCC between 2016 and 2019. Included were a total of 29 patients from a single academic medical center with untreated OCSCC (≥T2, or clinically node positive) randomized 1:1 to receive neoadjuvant therapy with single agent nivolumab or combination nivolumab and ipilimumab followed by surgery and standard of care adjuvant therapy. INTERVENTIONS: The interventions in this study were FDG-PET/CT scans before (T0) and after (T1) preoperative immunotherapy. MAIN OUTCOMES AND MEASURES: Data collected from FDG-PET/CT scans included maximum standardized uptake value (SUVmax) of primary OCSCC and cervical lymph nodes (LNs) at T0 and T1 and new LN uptake and uptake consistent with radiologic immune-related adverse events (irAEs) at T1. Primary OCSCC pathologic response reported as percentages of viable vs nonviable tumor. The number of CD8+ cells/mm2 was determined in the primary tumor biopsy specimen and at surgery. RESULTS: There was no correlation between pathologic response and change in SUVmax in the primary OCSCC between T0 and T1. Out of 27 total participants, 13 had newly FDG-avid ipsilateral LNs at T1, most negative on pathology. A total of 9 had radiologic irAEs, most commonly sarcoid-like LN (7 of 27). No correlations were found between primary OCSCC SUVmax at T0 and CD8+ T-cell number in the primary tumor biopsy, and no correlations were found between primary OCSCC SUVmax at T1 and CD8+ T-cell number in the primary tumor at surgery. CONCLUSIONS AND RELEVANCE: There were no correlations between changes in FDG uptake after neoadjuvant immunotherapy and pathologic primary tumor response. Importantly, newly FDG-avid ipsilateral LNs following neoadjuvant immunotherapy were commonly observed but did not represent progressive disease or indicate pathologically disease positive nodes in most cases. These findings argue against altering surgical plans in this setting and suggest that the role of FDG-PET/CT may be limited as an early imaging biomarker for predicting pathologic response to preoperative immunotherapy for OCSCC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02919683.
IMPORTANCE: Neoadjuvant immunotherapy is a novel approach with the potential to improve outcomes for patients with oral cavity squamous cell cancer (OCSCC). Adverse events of varying severity are reported with immunotherapy, and a biomarker to predict response would be clinically useful to avoid toxic effects in those unlikely to benefit. OBJECTIVE: To correlate changes on fluoro-[18F]-deoxy-2-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scans with primary tumor pathologic response and immunologic biomarkers in patients with OCSCC receiving neoadjuvant immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of serial FDG-PET/CT scans obtained prospectively as part of a phase 2 open-label randomized clinical trial investigating neoadjuvant immunotherapy in patients with untreated OCSCC between 2016 and 2019. Included were a total of 29 patients from a single academic medical center with untreated OCSCC (≥T2, or clinically node positive) randomized 1:1 to receive neoadjuvant therapy with single agent nivolumab or combination nivolumab and ipilimumab followed by surgery and standard of care adjuvant therapy. INTERVENTIONS: The interventions in this study were FDG-PET/CT scans before (T0) and after (T1) preoperative immunotherapy. MAIN OUTCOMES AND MEASURES: Data collected from FDG-PET/CT scans included maximum standardized uptake value (SUVmax) of primary OCSCC and cervical lymph nodes (LNs) at T0 and T1 and new LN uptake and uptake consistent with radiologic immune-related adverse events (irAEs) at T1. Primary OCSCC pathologic response reported as percentages of viable vs nonviable tumor. The number of CD8+ cells/mm2 was determined in the primary tumor biopsy specimen and at surgery. RESULTS: There was no correlation between pathologic response and change in SUVmax in the primary OCSCC between T0 and T1. Out of 27 total participants, 13 had newly FDG-avid ipsilateral LNs at T1, most negative on pathology. A total of 9 had radiologic irAEs, most commonly sarcoid-like LN (7 of 27). No correlations were found between primary OCSCC SUVmax at T0 and CD8+ T-cell number in the primary tumor biopsy, and no correlations were found between primary OCSCC SUVmax at T1 and CD8+ T-cell number in the primary tumor at surgery. CONCLUSIONS AND RELEVANCE: There were no correlations between changes in FDG uptake after neoadjuvant immunotherapy and pathologic primary tumor response. Importantly, newly FDG-avid ipsilateral LNs following neoadjuvant immunotherapy were commonly observed but did not represent progressive disease or indicate pathologically disease positive nodes in most cases. These findings argue against altering surgical plans in this setting and suggest that the role of FDG-PET/CT may be limited as an early imaging biomarker for predicting pathologic response to preoperative immunotherapy for OCSCC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02919683.
Authors: Jake S O'Donnell; Esmée P Hoefsmit; Mark J Smyth; Christian U Blank; Michele W L Teng Journal: Clin Cancer Res Date: 2019-04-30 Impact factor: 12.531
Authors: Alexander M Menzies; Rodabe N Amaria; Elisa A Rozeman; Alexander C Huang; Michael T Tetzlaff; Bart A van de Wiel; Serigne Lo; Ahmad A Tarhini; Elizabeth M Burton; Thomas E Pennington; Robyn P M Saw; Xiaowei Xu; Giorgos C Karakousis; Paolo A Ascierto; Andrew J Spillane; Alexander C J van Akkooi; Michael A Davies; Tara C Mitchell; Hussein A Tawbi; Richard A Scolyer; Jennifer A Wargo; Christian U Blank; Georgina V Long Journal: Nat Med Date: 2021-02-08 Impact factor: 53.440
Authors: Neeta Pandit-Taskar; Michael A Postow; Matthew D Hellmann; James J Harding; Christopher A Barker; Joseph A O'Donoghue; Martha Ziolkowska; Shutian Ruan; Serge K Lyashchenko; Frank Tsai; Michael Farwell; Tara C Mitchell; Ron Korn; William Le; Jason S Lewis; Wolfgang A Weber; Deepak Behera; Ian Wilson; Michael Gordon; Anna M Wu; Jedd D Wolchok Journal: J Nucl Med Date: 2019-10-04 Impact factor: 10.057
Authors: Laura Marandino; Antonella Capozza; Marco Bandini; Daniele Raggi; Elena Farè; Filippo Pederzoli; Andrea Gallina; Umberto Capitanio; Marco Bianchi; Giorgio Gandaglia; Nicola Fossati; Maurizio Colecchia; Patrizia Giannatempo; Gianluca Serafini; Barbara Padovano; Andrea Salonia; Alberto Briganti; Francesco Montorsi; Alessandra Alessi; Andrea Necchi Journal: Eur Urol Focus Date: 2020-11-07
Authors: Laura Marandino; Antonella Capozza; Marco Bandini; Daniele Raggi; Elena Farè; Filippo Pederzoli; Andrea Gallina; Umberto Capitanio; Marco Bianchi; Giorgio Gandaglia; Nicola Fossati; Maurizio Colecchia; Patrizia Giannatempo; Gianluca Serafini; Barbara Padovano; Andrea Salonia; Alberto Briganti; Francesco Montorsi; Alessandra Alessi; Andrea Necchi Journal: Urol Oncol Date: 2020-10-16 Impact factor: 3.498
Authors: Jonathan D Schoenfeld; Glenn J Hanna; Vickie Y Jo; Bhupendra Rawal; Yu-Hui Chen; Paul S Catalano; Ana Lako; Zoe Ciantra; Jason L Weirather; Shana Criscitiello; Adrienne Luoma; Nicole Chau; Jochen Lorch; Jason I Kass; Donald Annino; Laura Goguen; Anupam Desai; Brendan Ross; Hina J Shah; Heather A Jacene; Danielle N Margalit; Roy B Tishler; Kai W Wucherpfennig; Scott J Rodig; Ravindra Uppaluri; Robert I Haddad Journal: JAMA Oncol Date: 2020-10-01 Impact factor: 31.777